Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 14, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary Shares of 25 pence each.
- Purchase Date: December 14, 2012.
- Price Range: Highest price paid was 1,372.0 pence per share; lowest price paid was 1,359.5 pence per share.
- Treasury Holdings (Settled): 493,341,327 shares (9.14% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,951,327 shares (10.09% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,903,967,895 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 550,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.09% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (493,341,327 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (4,903,967,895 shares in issue) for disclosure threshold assessments.
- Check the remaining authorization limit for share buybacks following this transaction.
- Note that this filing does not contain financial performance data; refer to Form 20-F for full financial statements.